Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy

12. november 2026 opdateret af: Case Comprehensive Cancer Center

GUIDANCE-MIBC: Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy

This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Detaljeret beskrivelse

Muscle-invasive bladder cancer is an aggressive form of cancer with a high chance of metastasis at the time of diagnosis. The standard of care treatment for MIBC is neoadjuvant chemotherapy (NAC), followed by radical cystectomy or removal of the entire bladder, and then pelvic lymph node dissection. While NAC improves the overall survival at 5 years, it is associated with significant toxicities and there are many patient who do not benefit from it. Because of this, there is a need for predictive biomarkers to identify participants who can directly go into surgery without undergoing NAC. Recent studies have shown circulating tumor DNA (ctDNA) to be highly sensitive and specific predictive biomarker, and ctDNA negative participants have excellent outcomes and that skipping NAC is not harmful for these participants. The aim of this study is find out the safety and efficacy of omitting NAC in participants with MIBC who are ctDNA negative before their planned radical cystectomy. By using personalized ctDNA biomarkers, this will help spare patients the toxicity and delay unnecessary chemotherapy while still maintaining excellent outcomes.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

150

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Laura Bukavina, MD, MPH, MSc
  • Telefonnummer: (216) 444-6043
  • E-mail: bukavil2@ccf.org

Undersøgelse Kontakt Backup

  • Navn: Myra Krnac
  • Telefonnummer: (216)444-1047
  • E-mail: krnacm@ccf.org

Studiesteder

    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • Cleveland Clinic Foundation
        • Kontakt:
          • Laura Bukavina, MD, MPH, MSc
          • Telefonnummer: (216) 444-6043
          • E-mail: bukavil2@ccf.org
        • Ledende efterforsker:
          • Laura Bukavina, MD, MPH, MSc

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0).
  • Planned for radical cystectomy with curative intent.
  • Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any systemic therapy. Must have 2 negative tests within the screening window.
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
  • Adequate organ function as defined by standard laboratory criteria.
  • Ability to understand and provide written informed consent.

Exclusion Criteria:

  • Evidence of clinical node-positive or metastatic disease (cN+ or cM1) on baseline imaging.
  • Prior systemic therapy (chemotherapy or immunotherapy) for urothelial carcinoma within the past 12 months.
  • Positive ctDNA status at baseline (defined as a positive result on either of the two pre-operative Natera Signatera tests).
  • Variant histology comprising >50% of the tumor volume (e.g., small cell, sarcomatoid, plasmacytoid).
  • Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness that would limit compliance with study requirements.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ctDNA-negative MIBC

There will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments.

Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Recurrence free survival (RFS)
Tidsramme: 2 years

RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first.

2 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall survival (OS)
Tidsramme: at 2 years

Overall survival is defined as the duration of time from the start of treatment to time of death from any cause.

at 2 years
Overall survival
Tidsramme: at 5 years

Overall survival is defined as the duration of time from the start of treatment to time of death from any cause.

at 5 years
Rate of pathological complete response (pCR)
Tidsramme: at day 0

To assess the rate of pathological complete response and pathological tumor characteristics at the time cystectomy.

at day 0
Rates of surgical morbidity
Tidsramme: up to 4 weeks

To evaluate surgical morbidity in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy.

up to 4 weeks
Rates of complications
Tidsramme: up to 4 weeks

To evaluate complications in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy.

up to 4 weeks
Positive predictive value
Tidsramme: days -42 to 0

To evaluate the positive predictive value of baseline ctDNA status for pathological lymph node involvement

days -42 to 0
Negative predictive value
Tidsramme: days -42 to 0

To evaluate the negative predictive value of baseline ctDNA status for pathological lymph node involvement

days -42 to 0

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Laura Bukavina, MD, MPH, MSc, The Cleveland Clinic

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. januar 2029

Studieafslutning (Anslået)

1. december 2032

Datoer for studieregistrering

Først indsendt

12. november 2026

Først indsendt, der opfyldte QC-kriterier

12. november 2026

Først opslået (Faktiske)

18. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

There is not currently an intention or plan to share IPD

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner